Torvutatug samrotecan not checked
AstraZeneca · AZD5335 · AZ14170132
FollowEvery change as it happens, and a Monday email
Trials
5 active
5 in total · 3 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “FRa targeting antibody drug conjugate Topoisomerase I inhibitor”In the company’s words, NCT07816666 on ClinicalTrials.gov
- Tested for
- Epithelial Ovarian Cancer (2 trials), Ovarian Cancer (2 trials), Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma and 2 more
- Main trialPhase 3
- “The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)”In the company’s words, NCT07816666 on ClinicalTrials.gov
- Other names
- AZD5335 · AZ14170132 · Torvu-sam
Other drugs for Epithelial Ovarian Cancer
- OregovomabCanariaBio Inc. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- BL-M07D1Sichuan Baili (Biokin, SystImmune) · Phase 3
- BG-C9074BeOne Medicines (BeiGene) · Phase 3
Coming up5
- 15 Oct 2027Phase 1 trial completes · ClinicalTrials.gov
- 4 Aug 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 29 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 17 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 29 Sep 2028 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | |
| Phase 3Recruiting | 17 Nov 2028 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | |
| Phase 3Recruiting | 28 Jun 2030 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer | |
| Phase 1/2Recruiting | 4 Aug 2028 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | |
| Phase 1Recruiting | 15 Oct 2027 | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026